Search

IMI at the International Myopia Conference 2024

October 9, 2024
The International Myopia Conference was held in Hainan, China, from the 25th to the 28th of September and featured over 1000 attendees from 44 different countries.
 
The IMI 2025 White Paper Presentations and the series of IMI Debates were a great success, with strong engagement from the crowd and a fantastic turnout.
 
A complete recording of the event can be found at the link below. To view the IMI sessions, skip to timestamp 21:49.
 
A full list of the debate topics and speakers from the event can be found below. 

The speakers are now preparing point-counterpoint arguments to be published in a special issue of the Ophthalmic and Physiological Optics (OPO) journal which is expected to be published mid 2025.

The special issue of OPO will also include editorials, award papers and general papers on myopia. If you presented a paper or poster at this meeting, we invite you to submit a manuscript for consideration in the special issue.

Submission window: 1 December 2024 to 15 February 2025.

For publication: June 2025 (projected).

All manuscripts will be peer reviewed and must be submitted online via the link here.

Author Guidelines are available via the link here.

Authors should indicate that their manuscript is being submitted for the 2024 International Myopia Conference (IMC), Hainan, China special issue.

If you have any questions, please contact the Editor-in-Chief, Prof. Mark Rosenfield (opo@sunyopt.edu).

IMI DEBATES AT IMC – Sept 28,2024 11.30am

SPEAKER 1

SPEAKER 2

Can short-term changes in the choroid in humans predict long term eye growth?

Lisa Ostrin (No)

Ranjay Chakraborty (Yes)

Should combination therapies be the standard of care to maximize treatment efficacy for myopia control?

Padmaja Sankaridurg (No)

Audrey chia (Yes)

Is myopia more environmentally driven or genetically driven?

Virginie Verhoeven (Genetic)

Ian Morgan (Environment)

Are axial length percentile growth charts useful for myopia management?

Mark Bullimore (No)

Caroline Klaver (Yes)

Should %’s be used to represent efficacy of treatments or absolute values?

Noel Brennan (Absolute)

Paul Chamberlain/Arthur Bradley (%)

Does 0.01% atropine have a place as a myopia control therapy?

Safal Khanal (No)

Jason Yam (Yes)

Do we need to treat all young myopic patients or just those at recognized high risk of myopia progression?

Hedy (No)

Nicola Logan (Yes)

Can we accurately predict which high myopes will develop pathological myopia?

Ian Flitcroft (No)

Dr. Donny Hoang (Yes)

Must animal studies be done before clinical trial of myopia control therapies in humans?

Mingguang He (No)

Machelle Pardue (Yes)

Is the central retina critical for eye growth regulation?

Frank Schaeffel (No)

Chris Wildsoet (Yes)

No citation data has been entered for this IMI Whitepaper